Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
Date:3/3/2011

pany's DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the belief that Anadys is well-positioned to create value in the evolving HCV landscape; (ii) Anadys' objective to extend the favorable results seen last year when ANA598 was dosed over 12 weeks with the recently initiated Phase IIb study; (iii) the belief that the ANA598 Phase IIb study should set the stage for Phase III development; (iv) the ability for patients to achieve SVR24 in the ANA598 Phase IIb study; (v) the timing, occurrence and outcome of expected milestone events; and (vi) the plans and expected trial design for advancing ANA773 in development for HCV.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its abil
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals Augments Management Team and Board of Directors
2. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
3. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
4. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
5. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
6. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
7. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
8. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
10. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
(Date:9/19/2014)... NEW YORK , Sept. 19, 2014  An ... common forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) ... feet and legs, causing extreme muscle atrophy, weakness, and ... in the US and millions worldwide. CMT is a ... use of their legs, requiring mobility devices such as ...
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... Massachusetts , September 19, 2014 ... the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... of science and medical research in the field of ... Merck KGaA, Darmstadt, Germany , today ... Innovation (GGI) for 2014. The awards were announced during ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... Hi-Bred Biotechnology Leadership ... at Beijing Ag Summit, ... public and private sectors will help increase,farm productivity in the country ... vice president -- DuPont Crop,Genetics Research and Development, told attendees at ...
... 25 IDEXX,Laboratories, Inc. (Nasdaq: IDXX ), today ... 18% to $249.1 million from $211.2 million,for the first ... the,quarter ended March 31, 2008 were $0.43, compared to ... adjusted diluted EPS for the first,quarter grew 21% to ...
... (Nasdaq: KOSN ) will announce its first quarter ... close., The announcement of Kosan,s first quarter 2008 ... live webcast on May 1, 2008 at 1:30,p.m. Pacific ... live,call by dialing 888.680.0878 (US) or 617.213.4855 (international), access,code ...
Cached Biology Technology:DuPont Partnering with China to Increase Farm Productivity 2DuPont Partnering with China to Increase Farm Productivity 3IDEXX Laboratories Announces First Quarter Results 2IDEXX Laboratories Announces First Quarter Results 3IDEXX Laboratories Announces First Quarter Results 4IDEXX Laboratories Announces First Quarter Results 5IDEXX Laboratories Announces First Quarter Results 6IDEXX Laboratories Announces First Quarter Results 7IDEXX Laboratories Announces First Quarter Results 8IDEXX Laboratories Announces First Quarter Results 9IDEXX Laboratories Announces First Quarter Results 10IDEXX Laboratories Announces First Quarter Results 11IDEXX Laboratories Announces First Quarter Results 12IDEXX Laboratories Announces First Quarter Results 13IDEXX Laboratories Announces First Quarter Results 14IDEXX Laboratories Announces First Quarter Results 15IDEXX Laboratories Announces First Quarter Results 16IDEXX Laboratories Announces First Quarter Results 17Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results 2
(Date:9/18/2014)... fall foliage season that prompts millions of Americans to undertake ... and possibly last a little longer within a century, according ... peeping in some areas of the United States as summer ... in the journal Global Ecology and Biogeography . For ... is the state tree of New Hampshire could change ...
(Date:9/18/2014)... ALEXANDRIA, Va.Sept. 18, 2014Many Americans across racial and ... the greatest impact on their day-to-day life, more ... memory, hearing and speech (57% of African-Americans, 49% ... of Hispanics). When asked which disease or ailment ... blindness ranked first among African-Americans followed by AIDS/HIV. ...
(Date:9/18/2014)... 18, 2014 Elsevier, a world-leading provider of ... and the Australasian Research Management Society (ARMS), recognized ... at the 5th Scopus Young Researcher of the ... today at the National Convention Centre and in ... attended by guests representing Australia,s and New Zealand,s ...
Breaking Biology News(10 mins):Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2
... are atmospheric materials so small that they can,t be seen with ... patterns and human health all over the world and not ... of researchers at Texas A&M University. , Researchers Renyi Zhang, Alexei ... the Departments of Atmospheric Sciences and Chemistry say that nanoparticles appear ...
... St. Louis, MO, March 1, 2010 2009 estimates ... of ovarian cancer would be diagnosed and 14,600 women would ... ovarian cancer has an asymptomatic onset and a relatively low ... survivorship is critical. A study published in the March 2010 ...
... Between 5 and 10 percent of babies with Down syndrome ... its own. However, for reasons that haven,t been clear, 20 ... serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), ... cells and platelets. Now, researchers at Children,s Hospital Boston have ...
Cached Biology News:Atmospheric nanoparticles impact health, weather professor says 2Dietary factors influence ovarian cancer survival rates 2Key player found for a cancer typical in Down syndrome 2Key player found for a cancer typical in Down syndrome 3
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
... provide rapid and efficient removal of short ... salts from PCR products (Figure 1). The ... Binding Buffer options for fragments >100 bp ... in either single column or 96-well plate ...
... with the translation boosting Cap 1 structure. ... (versus 40% to 80% capped using co-transcriptional ... hours. mScript™ also features the Cap 1 ... up to 50% more efficient in in ...
... Expression System with Gateway™ Technology is ... containing the polyhedrin promoter. The expression ... genome (bacmid DNA) by site-specific transposition ... The recombinant bacmid DNA is then ...
Biology Products: